• Alexis Ogdie, Maarten de Wit, Callis Duffin Kristina K From Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; University of Utah, Salt Lak, Willemina Campbell, Jeffrey Chau, Laura C Coates, Lihi Eder, Musaab Elmamoun, Oliver FitzGerald, Dafna D Gladman, Niti Goel, Jana James, Umut Kalyoncu, John Latella, Chris Lindsay, Philip J Mease, Denis O'Sullivan, Ingrid Steinkoenig, Vibeke Strand, William Tillett, and Ana-Maria Orbai.
• From Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; University of Utah, Salt Lake City, Utah; QuintilesIMS, Denver, Colorado; Duke University School of Medicine, Durham, North Carolina; Rheumatology Research, Swedish Medical Center; University of Washington School of Medicine, Seattle, Washington; International Dermatology Outcome Measurers, West Granby, Connecticut; Cleveland Clinic, Cleveland, Ohio; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California; Johns Hopkins University School of Medicine; Psoriatic Arthritis Program, Johns Hopkins Arthritis Center, Baltimore, Maryland, USA; VU Medical Centre, Amsterdam, the Netherlands; University of Toronto; Krembil Research Institute; Psoriatic Disease Program, Toronto Western Hospital; Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada; Hong Kong Psoriatic Arthritis Association, Hong Kong, China; UK National Institute for Health Research (NIHR), Leeds; Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; Royal United Hospital; Royal United Hospital; Pharmacy and Pharmacology, University of Bath, UK; Newman Clinical Research Professor, St. Vincent's University Hospital and University College Dublin; Our Lady's Hospice and Care Services, Dublin, Ireland; Internal Medicine, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey. alexis.ogdie@uphs.upenn.edu.
• J Rheumatol. 2017 May 1; 44 (5): 697-700.

AbstractThe Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Outcome Measures in Rheumatology (OMERACT) Psoriatic Arthritis (PsA) Core Set working group recently published the updated 2016 psoriatic arthritis (PsA) core domain set, a set of disease features that should be measured in all clinical trials. At the GRAPPA annual meeting in July 2016, the PsA working group presented the updated PsA core domain set endorsed by 90% of participants at OMERACT in May 2016 and drafted a roadmap for the development of the PsA core outcome measurement set. In this manuscript, we review the development process of the PsA core domain set and the ongoing and proposed work streams for development of a PsA core measurement set.

14 keywords...

hide…